ArticleCytotechnology2021
Exosomes derived from mesenchymal stem cells curbs the progression of clear cell renal cell carcinoma through T-cell immune response.
Article in Cytotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- The multifaceted roles of mesenchymal stem cell-derived exosomes in digestive system malignancies: mechanisms and therapeutic implications.Frontiers in cell and developmental biology · 2026Review
- Progress of mesenchymal stem cell-derived exosomes in targeted delivery of antitumor drugs.Cancer cell international · 2025Review
- Extracellular vesicles and miRNA-based therapies in triple-negative breast cancer: advances and clinical perspectives.Extracellular vesicles and circulating nucleic acids · 2025Review
- How Advanced Are Extracellular Vesicles in Renal Cell Carcinoma? For Diagnostic and Therapeutic Frontiers.International journal of nanomedicine · 2025Review
- Emerging roles of exosomes in the diagnosis and treatment of kidney diseases.Frontiers in pharmacology · 2025Review
- Diagnostic, prognostic, and therapeutic potential of exosomal microRNAs in renal cancer.Pharmacological reports : PR · 2024Review
- Tumorigenic and tumoricidal properties of exosomes in cancers; a forward look.Cell communication and signaling : CCS · 2024Review
- Mesenchymal stem cell-derived microRNAs: Friends or foes of tumor cells?Histology and histopathology · 2023Review
- Exosomes in the Diagnosis and Treatment of Renal Cell Cancer.International journal of molecular sciences · 2023Review
- Emerging Roles of Using Small Extracellular Vesicles as an Anti-Cancer Drug.International journal of molecular sciences · 2023Review
- The role of MSCs and CAR-MSCs in cellular immunotherapy.Cell communication and signaling : CCS · 2023Review
- Emerging Roles of Mesenchymal Stem/Stromal-Cell-Derived Extracellular Vesicles in Cancer Therapy.Pharmaceutics · 2023Review
- Importance and implications of exosomes in nephrology and urology.Pflugers Archiv : European journal of physiology · 2023Review
- Extracellular vesicles in renal cell carcinoma: challenges and opportunities coexist.Frontiers in immunology · 2023Review
- Harnessing Normal and Engineered Mesenchymal Stem Cells Derived Exosomes for Cancer Therapy: Opportunity and Challenges.International journal of molecular sciences · 2022Review
- Mesenchymal stem cells-based therapy in liver diseases.Molecular biomedicine · 2022Review
- Mesenchymal Stem Cell-Derived Small Extracellular Vesicles: A Novel Approach for Kidney Disease Treatment.International journal of nanomedicine · 2022Review
- Exosomes in Renal Cell Cancer: Diagnostic and Therapeutic Nanovehicles.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exosomes derived from mesenchymal stem cells (MSC-Exo) are effective in modulating immunity. However, the role of MSC-Exo in clear cell renal cell carcinoma (ccRCC) is unclear. Our study was performed to identify if exosomal microRNA (miRNA) can be used as potential noninvasive biomarkers for ccRCC therapy. An orthotopic ccRCC mouse model was established, followed by MSC-Exo injection (1 mL, 20 μg/mL). The metastases of tumors were observed using HE staining, while number of dendritic cells, natural killing (NK) T cells and CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.